- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00327652
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
April 22, 2008 updated by: Anza Therapeutics, Inc.
Phase 1 Dose-Escalation Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
This clinical trial evaluated the safety and tolerability of CRS-100, an investigational agent containing a live-attenuated strain of Listeria monocytogenes (Lm).
CRS-100 is attenuated by genetic modification to limit cell to cell spread and invasion of liver cells.
These attenuations result in decreased virulence of CRS-100 in mice but retain the ability of the investigational agent to stimulate immunity in test animals and generate anti-tumor activity in mice.
The primary objective of this study was to determine the maximum tolerated dose (MTD) and to explore the safety profile of a single intravenous dose of CRS-100 in consenting volunteers.
Immunological response to CRS-100 and tumor status of study participants were also measured.
Participation in this first clinical trial with CRS-100 was restricted to adults with carcinoma refractory to standard treatment (or for whom no standard treatment is available) and who additionally had liver metastases.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients who consented to participate in the study were evaluated for eligibility according to their medical history, physical examination, blood testing, and computed tomography (CT) scan of thorax, abdomen, and pelvis.
Those patients who qualified for the study received a single intravenous dose of CRS-100 on study day 1, after which they remained in the hospital for five days for safety monitoring of health status, including serial blood collections.
Study participants returned for out-patient follow-up for further blood tests and additional monitoring of safety and immune response to CRS-100.
At day 56, after administration of CRS-100, participants had a repeat CT scan to measure tumor size, and they were then discharged from the study.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Johns Hopkins University
-
-
Texas
-
Dallas, Texas, United States, 75201
- Mary Crowley Medical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria (abbreviated):
- Documented carcinoma refractory to standard treatment (or for whom no standard treatment is available). Hepatocellular carcinoma (HCC) is not allowed.
- Hepatic metastases
- ECOG Performance Status of 0 or 1, or Karnofsky Performance Status (KPS) of 80% to 100%.
- Adequate organ function as defined by clinical hematology and chemistry assays.
Exclusion Criteria (abbreviated):
- Known central nervous system metastases.
- History of allergic reactions attributed to sulfa or beta-lactam antibiotics.
- Cardiac conditions associated with high- or moderate-risk of endocarditis.
- Intra-arterial hepatic catheter, hepatic cirrhosis, or clinically relevant ascites.
- Artificial (prosthetic) joint or other artificial implant or devices that cannot easily be removed.
- Known coagulation disorder or recent thromboembolic event.
- Use of immunosuppressive agent, chemotherapy, or radiation therapy within 28 days prior to CRS-100; bone marrow or stem cell transplant or a major organ allograft; autoimmune disease.
- Current history of gallstones or kidney stones.
- Infection with HIV, human t-lymphotropic virus type 1 (HTLV-1), hepatitis c virus (HCV), or hepatitis b virus (HBV).
- Pregnant or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose-limiting toxicities (DLTs) for 7 days after dosing
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
May 17, 2006
First Submitted That Met QC Criteria
May 17, 2006
First Posted (Estimate)
May 18, 2006
Study Record Updates
Last Update Posted (Estimate)
April 24, 2008
Last Update Submitted That Met QC Criteria
April 22, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC05001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Clinical Trials on CRS-100
-
CAI HongbingRecruitingOvarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer, Epithelial | Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | Homologous Recombination Repair Gene MutationChina
-
University of California, San DiegoRecruitingColorectal Cancer | Ovarian Carcinoma | Peritoneal Metastases | Appendix CancerUnited States
-
Uppsala University HospitalRecruitingColorectal Cancer, Peritoneal Carcinomatosis, Anastomosis InsufficiencySweden
-
University of ZurichUnknownPeritoneal CancerSwitzerland
-
Temple UniversitySpectrum Health Hospitals; National Rehabilitation Hospital, Dublin, Ireland... and other collaboratorsUnknownBrain InjuriesUnited States
-
BDH-Klinik Hessisch OldendorfRecruitingStroke | Traumatic Brain Injury | Neurologic Disorder | Disorder of Consciousness | Hypoxic-Ischemic EncephalopathyGermany
-
National Taiwan University HospitalRecruitingGastric Cancer | Peritoneal CarcinomatosisTaiwan
-
Hangzhou Normal UniversityCompletedPsychological Distress | Anxiety Depression | Disorders of Consciousness | Burden, CaregiverChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEnrolling by invitationOvarian Cancer | Neoadjuvant Chemotherapy | Prognostic Cancer ModelChina